Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: Reclassified Revenues Help Novartis's Fourth Quarter

Last-Minute Revenue Reclassifications Are Probably Not Reproducible

Executive Summary

A one-off revenue rabbit brought out of the hat may have helped Novartis's fourth-quarter sales but its analysts and investors were not impressed.

You may also be interested in...



Stock Watch: Johnson & Johnson's Fast And Slow Lanes

With all the commentary on J&J’s acquisition strategy and its consumer spin-off, the fourth-quarter performance of its pharmaceutical division went almost unnoticed.

Novartis Opts For Alliance Rather Than Acquisition With Alnylam

The announcement that the Swiss giant is collaborating again with Alnylam could spark fresh speculation that the firms are moving closer to a merger – or not.

Stock Watch: One Acquisition Does Not Make A Biotech M&A Boom

Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel